London, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of the “mRNA Therapeutics and mRNA Vaccines Market, 2022–2035” report to its list of offerings.
The mRNA therapeutics and mRNA vaccines market is currently abuzz with activity; industry players have forged several strategic alliances and received significant financial support from investors. This can be attributed to the various benefits offered by these therapeutic modalities, such as ease of administration, higher biological efficacy, enhanced potent immunogenicity and versatile delivery platforms at reduced toxicity levels.
To order this 270+ page report, which features 130+ figures and 140+ tables, please visit this https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html
Key Market Insights
More than 195 mRNA therapeutics candidates are currently under development
Over 55% candidates in the overall pipeline are mRNA vaccines; of these, 56% are being evaluated in early stages of development. It is worth mentioning that most of the mRNA therapeutics and mRNA vaccines are being developed for the treatment of infectious diseases. Further, majority of the mRNA drugs (43%) are delivered via the intramuscular route.
35+ companies claim to be engaged in the development of mRNA therapeutics and mRNA vaccines
It is worth noting that 87% of the companies active in this domain have been established since 2006. Further, around 50% of the mRNA drug developers are small firms. In addition, majority (43%) of these players are based in North America, primarily in the US.
~435 patents have been filed / granted for mRNA therapeutics and mRNA vaccines, since 2016
Owing to the rising research efforts of several industry and non-industry players engaged in this domain, more than 80% of the patent applications have been filed post 2018. It is worth noting that, majority (35%) of the patents were filed / granted in the US. This was followed by the patents filed / granted with the World Intellectual Property Organization (28%).
Partnership activity in mRNA therapeutics and mRNA vaccines market has increased at a CAGR of 54%, during the period 2013-2021
It is worth mentioning that the maximum number of partnerships were inked in 2021. Further, supply agreements emerged as the most popular type of partnership model adopted by mRNA therapeutics and mRNA vaccines developers, representing nearly 20% of the total partnership instances.
Over USD 11.5 billion has been invested by both private and public investors, since 2010
The maximum funding amount was raised through venture capital funding (33%), secondary offerings (20%) and grants (17%), during the period 2010-2022. It is worth highlighting that around 50% of the funding instances were reported by players based in the US.
175+ clinical trials evaluating mRNA therapeutics and mRNA vaccines have been registered, worldwide
The clinical research activity (in terms of number of trials registered) increased at a CAGR of 55%, during the period 2017-2022. Of the total number of trials, 22% have already been completed, while 67% studies are presently active, not recruiting and recruiting.
North America and Asia-Pacific are anticipated to capture over 75% of the market share, in 2035
In the long term, nearly 65% of the market revenues are expected to be generated from sales of therapeutics and vaccines targeting infectious diseases. Further, drugs designed for delivery via the intramuscular route are expected to occupy a larger share (62%) of the overall market size in 2035.
To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market/request-sample.html
Key Questions Answered
- Which are the key players engaged in the development of mRNA therapeutics and mRNA vaccines?
- Which mRNA therapy candidates are being evaluated across early and late stages of clinical development?
- Which are the key therapeutic areas targeted by mRNA therapeutics and mRNA vaccines?
- Which types of delivery systems are primarily being used for the administration of mRNA therapeutics and mRNA vaccines?
- Which are the most active trial sites (in terms of number of clinical studies being conducted) related to mRNA therapeutics and mRNA vaccines?
- Which companies are actively filing patents in order to drive innovation in the field of mRNA therapeutics and mRNA vaccines?
- What types of partnership models are commonly adopted by stakeholders in the mRNA therapeutics and vaccines domain?
- Which companies are making significant investments in this domain?
- How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the mRNA therapeutics and vaccines market has been analyzed across the following segments:
Routes of Administration
- Intradermal
- Intravenous
- Intranasal
- Others
Therapeutic Area
- Infectious Diseases
- Oncological Disorders
- Other Disorders
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and North Africa
The research includes detailed profiles of drugs being developed by key players (listed below); each profile features an overview of the drug, details related to the technology employed, current development status of the candidate and recent clinical trial results.
- Arcturus Therapeutics
- BioNTech and Pfizer
- CureVac
- Gennova
- Moderna
- Walvax
For additional details, please visit
https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
- CAR-T Cell Therapy Market: Industry Trends and Global Forecasts, 2022-2035
- Bacteriophage Therapy Market: Industry Trends and Global Forecasts, 2022-2035
- Rare Kidney Diseases Market: Industry Trends and Global Forecasts, 2022-2035
- Antiviral Drugs Market: Industry Trends and Global Forecasts, 2022-2035
